New hope for rare muscle disease: drug shows promise in early trial
NCT ID NCT07564271
First seen May 10, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study is testing a daily pill called deucravacitinib in 10 adults with active inflammatory muscle diseases (myositis) that haven't responded well to standard treatments. The goal is to see if the drug can reduce muscle inflammation and improve strength and daily function over 6 months. Researchers will also monitor safety and how the drug affects the immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.